Cite

HARVARD Citation

    Quhal, F. et al. (2021). Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma. Current opinion in urology. 31 (4), p. . [Online]. 
  
Back to record